Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes

Onswik is a once-weekly long-acting basal insulin analogue (insulin efsitora alfa-gobe) for subcutaneous injection. On 23 September 2026, FDA approved Onswik as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (FDA Human Drugs news page dated 24 Sep 2026; USPI Initial U.S. Approval: 2026, Revised: 09/2026). FDA framing: Onswik is the second once-weekly insulin approved for adults with type 2 diabetes (after Awiqli / insulin icodec-abae). It is not recommended for type 1 diabetes because of increased risk of severe hypoglycemia. Manufactured / marketed by Eli Lilly and Company. AE / support: 1-800-LillyRx (1-800-545-5979) or FDA MedWatch 1-800-FDA-1088.

Distinct path — not this carton (fact-only): Daily basal insulins (glargine, degludec, others), mealtime (bolus) insulin, GLP-1 / GIP–GLP-1 injectables, and oral diabetes medicines are not this weekly efsitora KwikPen. Awiqli (insulin icodec / insulin icodec-abae) is a different once-weekly basal insulin molecule and brand (Novo Nordisk) — already covered separately on Medcelerator. Do not mix pens or assume dose windows transfer between weekly brands. Today’s US labelled Onswik door is Lilly insulin efsitora alfa-gobe KwikPen (USPI 09/2026).

Where this is taking place

Commercial labelled door today: United States — FDA-labelled once-weekly basal for type 2 adults; U-500 and U-1,000 KwikPens (NDC 0002-5137-11 / 0002-5240-11). Company / HCP materials: pens available in the US in the coming months — confirm current pharmacy stock with the clinic. Diabetes / endocrinology prescription conversation — not a DIY import.

European Union: EC marketing authorisation 20 August 2026 (MA numbers EU/1/26/2049/001 and /002 on Swedish FASS SmPC; CHMP positive opinion 25 June 2026, EMEA/H/C/006388). SmPC indication: treatment of type 2 diabetes mellitus in adults. EMA overview page retrieved for this draft still emphasised the CHMP opinion stage in places — treat the dated SmPC first-authorisation line (20 Aug 2026) plus company “EMA approval” framing as the EC door, and ask the local clinic for current national launch status.

Japan (PMDA) / Mexico (COFEPRIS): Company FDA press release (24 Sep 2026) states prior regulatory actions there — national label text not independently retrieved for this draft; ask the local clinic rather than assuming a US pen is interchangeable.

Health Canada / MHRA / TGA / Swissmedic: Onswik authorisation not confirmed on sources used here.

QWINT Phase 3 programme (COMPLETED — evidence, not enrolment): NCT05662332 (QWINT-1), NCT05362058 (QWINT-2), NCT05275400 (QWINT-3), NCT05462756 (QWINT-4). Sponsor: Eli Lilly. These records are COMPLETED — not walk-in research access.

Approval matrix

Access by country

• United States: Ask a diabetes / endocrinology clinician about labelled Onswik if you have type 2 diabetes and are considering once-weekly basal insulin (insulin-naïve or switching from daily basal, with or without mealtime insulin). Path: confirm T2D → review hypoglycemia risk and pen training → prescribe U-500 or U-1,000 KwikPen → titrate per USPI → pharmacy fill when stocked. AE: 1-800-545-5979. No prices in this article.
• European Union: Ask the local diabetes clinic whether Onswik is launched and funded under the EC MA for adult type 2 diabetes.
• Canada / UK / Australia / other countries: Authorisation not confirmed here — ask what legal paths exist; do not import on your own.
• Japan / Mexico: Confirm the local labelled carton with the treating centre (company states prior approvals).

Who is eligible

United States (USPI 09/2026):

• Indication: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
• Limitations of use: Not recommended in type 1 diabetes mellitus (increased severe hypoglycemia risk).
• Pediatrics: Safety and effectiveness not established.
• Pregnancy / lactation: Use not recommended (USPI §8.1 / §8.2).
• Contraindications: During episodes of hypoglycemia; hypersensitivity to insulin efsitora alfa-gobe or any excipient.

European Union (SmPC 4.1): Treatment of type 2 diabetes mellitus in adults. EU SmPC also contraindicates second and third trimester pregnancy (wording differs from US “not recommended” framing — use the local label).

Not labelled on sources confirmed for this draft:

• Type 1 diabetes as an approved US population.
• Children / adolescents.
• Treating Onswik and Awiqli as interchangeable pens.

What the pivotal study showed (QWINT-1–4 / USPI §14)

Four randomized, open-label, treat-to-target, active-controlled Phase 3 trials; primary endpoint non-inferiority of HbA1c change versus daily basal insulin (margin 0.4%).

All four met pre-specified non-inferiority. Level 3 and/or level 2 hypoglycemia proportions on Onswik (USPI Table 4): Trial 1 25.9%, Trial 2 27.9%, Trial 3 40.9%, Trial 4 55.6% (higher when mealtime insulin was also used).

How it is taken

From the USPI (clinician individualises; this is not a home dose calculator):

• Inject once weekly on the same day; day-of-week may change if ≥4 days since last dose.
• Sites: abdomen, upper arm, thigh, or buttocks; rotate sites.
• U-500 KwikPen: 5-unit increments, up to 400 units/injection, 1,500 units/pen (NDC 0002-5137-11).
• U-1,000 KwikPen: 10-unit increments, up to 800 units/injection, 3,000 units/pen (NDC 0002-5240-11).
• Insulin-naïve fixed titration example (Trial 1 / USPI): start 100 units/week; escalate every 4 weeks as needed to 150 / 250 / 400.
• Switching from daily basal: stop daily basal; first Onswik dose the day after last daily basal; one-time starting dose rules depend on fasting glucose — do not repeat the one-time starting dose.
• Never withdraw Onswik into a syringe from the pen; never share pens; check the label every injection to avoid mix-ups with other weekly or daily injectables.
• In-use: use within 112 days (16 weeks) after first use; refrigerate preferentially; limited room-temperature window per USPI Table 11.

EU SmPC uses similar weekly logic with mmol/L fasting targets — follow the local SmPC when in the EU.

Safety (what the label puts first)

USPI warnings that lead:

• Hypoglycemia due to medication errors / accidental overdose — mix-ups with other insulins; never syringe-draw from the pen; do not repeat the one-time starting dose.
• Severe hypoglycemia in type 1 diabetes — not recommended.
• Hypoglycemia (may be life-threatening); longer recovery window possible because of long action.
• Hyperglycemia/hypoglycemia with insulin regimen changes — supervise switches.
• Hypersensitivity / anaphylaxis risk.
• Hypokalemia.
• Never share pens.
• Fluid retention / heart failure risk with concomitant PPAR-gamma agonists (TZDs).

Common adverse reactions (USPI): hypoglycemia, hypersensitivity reactions, injection-site reactions, lipodystrophy, pruritus, rash, edema, weight gain.

How to talk to a doctor

Bring this page to a diabetes / endocrinology clinician and ask:

1. “I have type 2 diabetes. Is labelled Onswik (weekly efsitora) a fit versus daily basal or Awiqli?”
2. “If I switch from daily basal, how will you calculate the first weekly dose and avoid repeating a one-time starter dose?”
3. “Which pen — U-500 or U-1,000 — and how do we train on the dial so we do not mix it with other weekly shots?”
4. “What glucose-check plan do we use in the first weeks, especially if I also take mealtime insulin or a GLP-1?”
5. If outside the US/EU: “Has our regulator authorised Onswik, or what legal options exist?”

Research and regulatory team (from sources only — no invented contacts)

• US applicant / manufacturer: Eli Lilly and Company (USPI; AE 1-800-545-5979).
• EU MAH: Eli Lilly Nederland B.V., Utrecht, Netherlands (FASS SmPC §7).
• QWINT sponsor: Eli Lilly (ClinicalTrials.gov records above).
• FDA public summary: FDA Approves Once-Weekly Insulin for Type 2 Diabetes Mellitus (content current as of 09/24/2026).
• Related Medcelerator context (distinct carton): Awiqli / insulin icodec — first weekly basal; different molecule.

Canada zoom: authorisation not confirmed

No Health Canada DIN / NOC for Onswik asserted on sources used here. Awiqli already has a Canadian door for a different weekly basal. Do not import a US Onswik pen as a Canadian care plan.

EU zoom: authorised — launch varies

EC MA 20 Aug 2026 for adult type 2 diabetes. National reimbursement and pharmacy stock still vary by member state. EU pregnancy contraindication language in the SmPC is stricter than the US “not recommended” line — follow the local SmPC.

Bottom line

Onswik is FDA-approved (23 Sep 2026) once-weekly basal insulin for adults with type 2 diabetes, with EU authorisation from 20 Aug 2026. QWINT-1–4 showed A1C reductions non-inferior to daily glargine or degludec. It is a Lilly efsitora carton — not Awiqli, not a type 1 product, and not funded just because it is authorised. Ask a diabetes clinician about pen training, switching math, and local stock.

Primary sources

1. FDA — Once-Weekly Insulin for Type 2 Diabetes Mellitus (24 Sep 2026 news page; action 23 Sep 2026 per Lilly).
2. Onswik USPI PDF — pi.lilly.com/us/onswik-uspi.pdf (Revised 09/2026); archived copy /workspace/drafts/_source-onswik-uspi-2026-09.pdf.
3. ClinicalTrials.gov — NCT05662332, NCT05362058, NCT05275400, NCT05462756.
4. EMA — Onswik EPAR (EMEA/H/C/006388); FASS SmPC first authorisation 20 Aug 2026, MA EU/1/26/2049.
5. Eli Lilly company release — 24 Sep 2026 (labeled as company; FDA/EMA dates cross-checked above).

---

Medcelerator draft — unpublished. Not medical advice. Authorized is not funded.